TRxADE HEALTH, Inc.
TRxADE HEALTH, Inc. (MEDS) Stock Competitors & Peer Comparison
See (MEDS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MEDS | $7.59 | +4.55% | 13.3M | -0.31 | -$24.38 | N/A |
| ONC | $305.74 | +3.81% | 34.4B | -83.99 | -$3.64 | N/A |
| INSM | $105.00 | +3.19% | 19.9B | -17.71 | -$5.93 | N/A |
| WBA | $11.62 | -0.09% | 10.1B | -1.59 | -$7.29 | +4.30% |
| HROWM | $26.68 | +0.11% | 1.3B | N/A | N/A | +11.17% |
| HROWL | $25.35 | -0.08% | 1.3B | N/A | N/A | N/A |
| LFMDP | $24.25 | +0.07% | 1.1B | -10.75 | -$2.26 | N/A |
| LFMD | $10.20 | -6.16% | 463.6M | -30.91 | -$0.33 | N/A |
| HITI | $2.15 | -5.29% | 174.2M | -23.89 | -$0.09 | N/A |
| PETS | $3.22 | -9.30% | 66.5M | 322.00 | $0.01 | N/A |
Stock Comparison
MEDS vs ONC Comparison July 2025
MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 13.3M. In comparison, ONC has a market cap of 34.4B. Regarding current trading prices, MEDS is priced at $7.59, while ONC trades at $305.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of -0.31, whereas ONC's P/E ratio is -83.99. In terms of profitability, MEDS's ROE is +0.22%, compared to ONC's ROE of -0.12%. Regarding short-term risk, MEDS is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check ONC's competition here
MEDS vs INSM Comparison July 2025
MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 13.3M. In comparison, INSM has a market cap of 19.9B. Regarding current trading prices, MEDS is priced at $7.59, while INSM trades at $105.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of -0.31, whereas INSM's P/E ratio is -17.71. In terms of profitability, MEDS's ROE is +0.22%, compared to INSM's ROE of -4.47%. Regarding short-term risk, MEDS is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check INSM's competition here
MEDS vs WBA Comparison July 2025
MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 13.3M. In comparison, WBA has a market cap of 10.1B. Regarding current trading prices, MEDS is priced at $7.59, while WBA trades at $11.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of -0.31, whereas WBA's P/E ratio is -1.59. In terms of profitability, MEDS's ROE is +0.22%, compared to WBA's ROE of -0.70%. Regarding short-term risk, MEDS is more volatile compared to WBA. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check WBA's competition here
MEDS vs HROWM Comparison July 2025
MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 13.3M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, MEDS is priced at $7.59, while HROWM trades at $26.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of -0.31, whereas HROWM's P/E ratio is N/A. In terms of profitability, MEDS's ROE is +0.22%, compared to HROWM's ROE of -0.28%. Regarding short-term risk, MEDS is more volatile compared to HROWM. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check HROWM's competition here
MEDS vs HROWL Comparison July 2025
MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 13.3M. In comparison, HROWL has a market cap of 1.3B. Regarding current trading prices, MEDS is priced at $7.59, while HROWL trades at $25.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of -0.31, whereas HROWL's P/E ratio is N/A. In terms of profitability, MEDS's ROE is +0.22%, compared to HROWL's ROE of -0.36%. Regarding short-term risk, MEDS is more volatile compared to HROWL. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check HROWL's competition here
MEDS vs LFMDP Comparison July 2025
MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 13.3M. In comparison, LFMDP has a market cap of 1.1B. Regarding current trading prices, MEDS is priced at $7.59, while LFMDP trades at $24.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of -0.31, whereas LFMDP's P/E ratio is -10.75. In terms of profitability, MEDS's ROE is +0.22%, compared to LFMDP's ROE of +2.33%. Regarding short-term risk, MEDS is more volatile compared to LFMDP. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check LFMDP's competition here
MEDS vs LFMD Comparison July 2025
MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 13.3M. In comparison, LFMD has a market cap of 463.6M. Regarding current trading prices, MEDS is priced at $7.59, while LFMD trades at $10.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of -0.31, whereas LFMD's P/E ratio is -30.91. In terms of profitability, MEDS's ROE is +0.22%, compared to LFMD's ROE of +2.33%. Regarding short-term risk, MEDS is more volatile compared to LFMD. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check LFMD's competition here
MEDS vs HITI Comparison July 2025
MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 13.3M. In comparison, HITI has a market cap of 174.2M. Regarding current trading prices, MEDS is priced at $7.59, while HITI trades at $2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of -0.31, whereas HITI's P/E ratio is -23.89. In terms of profitability, MEDS's ROE is +0.22%, compared to HITI's ROE of -0.07%. Regarding short-term risk, MEDS is more volatile compared to HITI. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check HITI's competition here
MEDS vs PETS Comparison July 2025
MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 13.3M. In comparison, PETS has a market cap of 66.5M. Regarding current trading prices, MEDS is priced at $7.59, while PETS trades at $3.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of -0.31, whereas PETS's P/E ratio is 322.00. In terms of profitability, MEDS's ROE is +0.22%, compared to PETS's ROE of +0.00%. Regarding short-term risk, MEDS is less volatile compared to PETS. This indicates potentially lower risk in terms of short-term price fluctuations for MEDS.Check PETS's competition here
MEDS vs YI Comparison July 2025
MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 13.3M. In comparison, YI has a market cap of 60.6M. Regarding current trading prices, MEDS is priced at $7.59, while YI trades at $6.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of -0.31, whereas YI's P/E ratio is -3.21. In terms of profitability, MEDS's ROE is +0.22%, compared to YI's ROE of +0.11%. Regarding short-term risk, MEDS is more volatile compared to YI. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check YI's competition here
MEDS vs RAD Comparison July 2025
MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 13.3M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, MEDS is priced at $7.59, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of -0.31, whereas RAD's P/E ratio is -0.05. In terms of profitability, MEDS's ROE is +0.22%, compared to RAD's ROE of +2.76%. Regarding short-term risk, MEDS is less volatile compared to RAD. This indicates potentially lower risk in terms of short-term price fluctuations for MEDS.Check RAD's competition here
MEDS vs RNTX Comparison July 2025
MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 13.3M. In comparison, RNTX has a market cap of 27.7M. Regarding current trading prices, MEDS is priced at $7.59, while RNTX trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of -0.31, whereas RNTX's P/E ratio is -0.43. In terms of profitability, MEDS's ROE is +0.22%, compared to RNTX's ROE of -1.12%. Regarding short-term risk, MEDS is less volatile compared to RNTX. This indicates potentially lower risk in terms of short-term price fluctuations for MEDS.Check RNTX's competition here
MEDS vs NEUP Comparison July 2025
MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 13.3M. In comparison, NEUP has a market cap of 15.9M. Regarding current trading prices, MEDS is priced at $7.59, while NEUP trades at $8.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of -0.31, whereas NEUP's P/E ratio is 0.45. In terms of profitability, MEDS's ROE is +0.22%, compared to NEUP's ROE of +0.31%. Regarding short-term risk, MEDS is more volatile compared to NEUP. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check NEUP's competition here
MEDS vs CJJD Comparison July 2025
MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 13.3M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, MEDS is priced at $7.59, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of -0.31, whereas CJJD's P/E ratio is -0.46. In terms of profitability, MEDS's ROE is +0.22%, compared to CJJD's ROE of -0.30%. Regarding short-term risk, MEDS is more volatile compared to CJJD. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check CJJD's competition here
MEDS vs SSY Comparison July 2025
MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 13.3M. In comparison, SSY has a market cap of 8.8M. Regarding current trading prices, MEDS is priced at $7.59, while SSY trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of -0.31, whereas SSY's P/E ratio is -3.20. In terms of profitability, MEDS's ROE is +0.22%, compared to SSY's ROE of +0.12%. Regarding short-term risk, MEDS is less volatile compared to SSY. This indicates potentially lower risk in terms of short-term price fluctuations for MEDS.Check SSY's competition here
MEDS vs MDVL Comparison July 2025
MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 13.3M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, MEDS is priced at $7.59, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of -0.31, whereas MDVL's P/E ratio is -0.05. In terms of profitability, MEDS's ROE is +0.22%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, MEDS is less volatile compared to MDVL. This indicates potentially lower risk in terms of short-term price fluctuations for MEDS.Check MDVL's competition here
MEDS vs LFLY Comparison July 2025
MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 13.3M. In comparison, LFLY has a market cap of 658.9K. Regarding current trading prices, MEDS is priced at $7.59, while LFLY trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of -0.31, whereas LFLY's P/E ratio is -0.12. In terms of profitability, MEDS's ROE is +0.22%, compared to LFLY's ROE of +0.34%. Regarding short-term risk, MEDS is more volatile compared to LFLY. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check LFLY's competition here
MEDS vs LFLYW Comparison July 2025
MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 13.3M. In comparison, LFLYW has a market cap of 580.4K. Regarding current trading prices, MEDS is priced at $7.59, while LFLYW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of -0.31, whereas LFLYW's P/E ratio is -0.06. In terms of profitability, MEDS's ROE is +0.22%, compared to LFLYW's ROE of +0.34%. Regarding short-term risk, MEDS is more volatile compared to LFLYW. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check LFLYW's competition here
MEDS vs ATNFW Comparison July 2025
MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 13.3M. In comparison, ATNFW has a market cap of 77.3K. Regarding current trading prices, MEDS is priced at $7.59, while ATNFW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of -0.31, whereas ATNFW's P/E ratio is N/A. In terms of profitability, MEDS's ROE is +0.22%, compared to ATNFW's ROE of -1.41%. Regarding short-term risk, MEDS is less volatile compared to ATNFW. This indicates potentially lower risk in terms of short-term price fluctuations for MEDS.Check ATNFW's competition here
MEDS vs BIMI Comparison July 2025
MEDS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 13.3M. In comparison, BIMI has a market cap of 2.3K. Regarding current trading prices, MEDS is priced at $7.59, while BIMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of -0.31, whereas BIMI's P/E ratio is N/A. In terms of profitability, MEDS's ROE is +0.22%, compared to BIMI's ROE of -2.93%. Regarding short-term risk, MEDS is more volatile compared to BIMI. This indicates potentially higher risk in terms of short-term price fluctuations for MEDS.Check BIMI's competition here